Antiviral Agents/therapeutic use; Hepatitis C/drug therapy; Interdisciplinary Communication; Interferon-alpha/therapeutic use; Patient Compliance/psychology; Polyethylene Glycols/therapeutic use; Ribavirin/therapeutic use; Self-Help Groups; Adolescent; Adult; Aged; Antiviral Agents/economics; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus/genetics; Humans; Interferon-alpha/economics; Male; Markov Chains; Middle Aged; Polyethylene Glycols/economics; Quality-Adjusted Life Years; Recombinant Proteins/economics; Recombinant Proteins/therapeutic use; Ribavirin/economics; Treatment Outcome; Young Adult

95% CI; 95% confidence interval; ALT; ANC; BOC; CHC; Cost-effectiveness; DAA; EOT; EPO; G-CSF; HADS; HBV; HCC; HCV; HIV; Hb; Hepatitis; ICER; MSP; NR; OR; PCR; PHQ; PLT; Programme; QALY; RBV; Response; SE; SVR; TVR; Treatment; ULN; absolute neutrophil count; alanine aminotransferase; boceprevir; chronic hepatitis C; direct-acting antivirals; end of treatment; erythropoietin; granulocyte colony-stimulating factor; haemoglobin; hepatitis B virus; hepatitis C virus; hepatocellular carcinoma; hospital anxiety and depression scale; human immunodeficiency virus; incremental cost-effectiveness ratio; multidisciplinary support programme; non-responders; odds ratio; patient health questionnaires; pegIFN; pegylated interferon; polymerase chain reaction; potentially life threatening; quality-adjusted life year; ribavirin; standard error; sustained virological response; telaprevir; upper limit of normal